Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Long-Term Investments (2018 - 2022)

CNBX Pharmaceuticals (CNBX) has disclosed Long-Term Investments for 5 consecutive years, with $116217.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Investments fell 79.39% year-over-year to $116217.0, compared with a TTM value of $116217.0 through Nov 2022, down 79.39%, and an annual FY2022 reading of $176087.0, down 79.17% over the prior year.
  • Long-Term Investments was $116217.0 for Q4 2022 at CNBX Pharmaceuticals, down from $176087.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $9.2 million in Q2 2019 and bottomed at $116217.0 in Q4 2022.
  • Average Long-Term Investments over 5 years is $2.3 million, with a median of $717470.0 recorded in 2018.
  • The sharpest move saw Long-Term Investments soared 919.28% in 2019, then tumbled 95.14% in 2020.
  • Year by year, Long-Term Investments stood at $1.0 million in 2018, then skyrocketed by 140.6% to $2.5 million in 2019, then rose by 23.1% to $3.0 million in 2020, then tumbled by 81.38% to $564007.0 in 2021, then tumbled by 79.39% to $116217.0 in 2022.
  • Business Quant data shows Long-Term Investments for CNBX at $116217.0 in Q4 2022, $176087.0 in Q3 2022, and $239478.0 in Q2 2022.